ReviewCureus2025
Clarifying the Spectrum of Gallbladder Haemorrhage: A Systematic Review of Haemorrhagic Cholecystitis and Haemorrhagic Gallbladder.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Haemorrhagic cholecystitis (HC) and haemorrhagic gallbladder (HGB) refer to rare clinical entities characterised by bleeding originating from the gallbladder. These terms are often used interchangeably in literature to describe a spectrum of presentations, ranging from incidental findings to life-threatening haemorrhage and shock. Reported cases are scarce and primarily limited to case reports and small series. Clinical presentation and management vary significantly, from conservative antibiotic therapy to urgent surgical intervention. This systematic review aims to summarise the published clinical experience, clarify terminology use, and propose a stratified management approach based on presentation severity. A systematic review of the literature was conducted in accordance with PRISMA guidelines, covering publications from January 2019 to May 2025. PubMed, Embase, Medline, and Google Scholar were searched using terms including "haemorrhagic cholecystitis", "haemorrhagic gallbladder", and "gallbladder haemorrhage". Only English-language studies reporting extractable patient-level data were included. Data collected included demographics, background comorbidities, anticoagulation status, presenting symptoms, haemodynamic findings, treatment modality, transfusion requirement, and mortality. Cases were stratified as haemorrhagic cholecystitis (HC) or haemorrhagic gallbladder (HGB) based on clinical severity, haemodynamic compromise, and treatment urgency. A total of 65 cases from 50 publications were included. The median age was 67 years (range 20-92), with a male predominance (63.1%). Anticoagulation was reported in 47.7% of cases. Typical symptoms such as right upper quadrant pain, fever, or vomiting were observed in 90.8%, while jaundice, gastrointestinal bleeding, and haemorrhagic shock occurred in 15.4%, 29.2%, and 16.9% of patients, respectively. Gallstones were present in 38.5% of cases. Multimodal treatment was the most commonly employed approach (30.8%), followed by urgent open cholecystectomy (26.2%) and urgent laparoscopic cholecystectomy (18.5%). The overall mortality rate was 10.8%. Retrospective stratification classified 73.8% of cases as HGB and 26.2% as HC. HC and HGB represent a continuum of gallbladder haemorrhage, with HC referring to stable patients managed conservatively or electively, and HGB reserved for those with haemodynamic instability requiring urgent intervention. Greater awareness is warranted in elderly patients on anticoagulation and in younger patients with atypical presentations or underlying systemic disease. A stratified management approach based on clinical severity is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.